Avid Bioservices Inc (CDMO)

[Protector]

biopharm, not sure if we understood the same thing here, but with "competitive enrolment" they do not mean competition for NSCLC patients between :

A) different clinical trials for NSCLC
B) different clinical centres in a same clinical trial

B is because they are far from each other anyway or in very large cities and so there is no need to compete with the other centre. I have coordinates now from each (except the 7 last - still working on it) clinical trial centres. So they really are not typical in a competing situation for the same patients.

What they mean (and the Italian document kind of says it) is that you can enrol until the total quota for a region (say Italy) a zone (say US, Europe, Asia or Australia) or even the complete international clinical trial is reached.

So the clinical centres that have many patients can enrol them and compensate for those that have few.

We also have prove (posted by huschi) SUNRISE was already advertised on some clinical trial web-sites such as this one on 25 NOVEMBER 2013. This increases the possibility that a number of centres had patients ready when the trail started DEC 30th, 2013.

Also found traces to Celgene and Tekada in relation with Bavituximab but need more time to shuffle everything in. So possible also for next week.

I don't know what it is but there is suddenly so much information available that never showed up before that it makes me dizzy.